trending Market Intelligence /marketintelligence/en/news-insights/trending/OtiTULVU96BX4oHyM-5qeg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Eisai's epilepsy treatment Fycompa wins regulatory nod in China

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Eisai's epilepsy treatment Fycompa wins regulatory nod in China

Eisai Co. Ltd. said its epilepsy treatment Fycompa, or perampanel, won regulatory approval from the National Medical Products Administration to market the drug in China.

The drug is now approved as an adjuvant treatment for partial onset seizures in epilepsy patients aged 12 and above, the Japanese company said in a release dated Oct. 15. Partial seizures occur when abnormal electrical activity happens in only one part of the brain.

Eisai submitted the application for the drug in September 2018 and was granted priority review by the Chinese regulator.

China has approximately 9 million patients with epilepsy, and 60% are affected by partial-onset seizures. About 40% of patients with partial-onset seizures require adjuvant treatments.

Fycompa has received regulatory approval in more than 60 countries as an adjuvant treatment for partial-onset seizures in patients with epilepsy aged 12 and above, Eisai said in the release.

The drug is also approved in over 55 countries as an adjuvant treatment for primary generalized tonic-clonic seizures in patients with epilepsy. Generalized tonic-clonic seizure is a type of seizure that usually occurs on both sides of the brain, or start on one side and spread to the whole brain.